

Xdemvy (lotilaner ophthalmic solution)
Effective 02/01/2024

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Exceptions	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029

Overview

Xdemvy is indicated for the treatment of Demodex blepharitis.

Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted when the following criteria is met:

1. Member has a diagnosis of Demodex blepharitis.
2. Member exhibits ONE of the following signs of Demodex infestation:
 - a. Collarettes
 - b. Eyelid margin erythema
 - c. Eyelash anomalies (e.g., eyelash misdirection)
3. Member is experiencing symptoms or architectural changes associated with Demodex infestation (e.g., burning, tearing, itching, foreign body sensation, eyelashes missing, eyelashes growing inward)
4. Provider attestation that member has had trial and inadequate response to tea tree oil.
5. The requested medication is prescribed by or in consultation with one of the following:
 - a. Ophthalmologist
 - b. Optometrist

Limitations

1. Approvals will be granted for 2 months.

References

1. Xdemvy Prescribing Information. Tarsus Pharmaceuticals, Inc. Irvine, CA. July 2023.

2. Rhee, M., Yeu, E., Barnett., M., et al. Demodex Blepharitis: A Comprehensive Review of the Disease, Current Management, and Emerging Therapies. Available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351901/>. Accessed October 26, 2023.
3. Clinical Consult with Ophthalmologist. September 13, 2023.
4. Zhang, A., Muntz, A., Wang, M., et al. Ocular Demodex: A systematic review of the clinical literature. Available at: [file:///C:/Users/kdekhtaw/Downloads/Zhang%20et%20al%202020_SR%20\(1\).pdf](file:///C:/Users/kdekhtaw/Downloads/Zhang%20et%20al%202020_SR%20(1).pdf). Accessed October 26, 2023.
5. ClinicalTrials.gov. Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (Saturn-1). Available at: <https://www.clinicaltrials.gov/study/NCT04784091?cond=demodex%20blepharitis&rank=4>. Accessed October 26, 2023.
6. ClinicalTrials.gov. Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (Saturn-2). Available at: <https://www.clinicaltrials.gov/study/NCT04784091?cond=demodex%20blepharitis&rank=4>. Accessed October 26, 2023.

Review History

12/13/2023: Created for December P&T; Effective 2/1/2024

